Back
News
1 min read

[Press Release] XAV19 : validation of the first dose of anti-Covid treatment of XENOTHERA

  • Bertrand Fabien
  • Author Bertrand Fabien
  • Published 12 novembre 2020

Related Posts

Reflections on #AACR2024: our key insights and contributions

April, 2024. The AACR Annual Meeting in San Diego was a pivotal...

Read More

XENOTHERA announces the start of the second dose cohort in the FIPO trial

March, 2024. FIPO is the first-in-human trial of XON7, the first anti-solid...

Read More

XENOTHERA : publication of the first-in-human trial of LIS1 in Solid Organ Transplantation

February, 2024. For almost ten years, XENOTHERA has been committed to tackling...

Read More

XENOTHERA

21 rue La Nouë de Fer, 44200 Nantes, France

contact@xenothera.com

Media : xenothera@izsogood.co

Linkedin-in